Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to 13.69%.

  • Indivior Pharmaceuticals' EBITDA Margin rose 22900.0% to 13.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.39%, marking a year-over-year increase of 85700.0%. This contributed to the annual value of 3.2% for FY2024, which is 35600.0% up from last year.
  • Indivior Pharmaceuticals' EBITDA Margin amounted to 13.69% in Q3 2025, which was up 22900.0% from 6.62% recorded in Q2 2025.
  • Indivior Pharmaceuticals' EBITDA Margin's 5-year high stood at 22.53% during Q1 2023, with a 5-year trough of 107.05% in Q4 2022.
  • Moreover, its 4-year median value for EBITDA Margin was 14.54% (2025), whereas its average is 1.64%.
  • Examining YoY changes over the last 5 years, Indivior Pharmaceuticals' EBITDA Margin showed a top increase of 1275300bps in 2023 and a maximum decrease of -653900bps in 2023.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' EBITDA Margin stood at 107.05% in 2022, then skyrocketed by 119bps to 20.48% in 2023, then decreased by -25bps to 15.44% in 2024, then dropped by -11bps to 13.69% in 2025.
  • Its EBITDA Margin stands at 13.69% for Q3 2025, versus 6.62% for Q2 2025 and 18.42% for Q1 2025.